Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR), University of Sheffield:

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

Professional or specialist and patient or carer groups:

Other consultees:

Commentator organisations (did not provide written evidence and without the right of appeal):

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying anti-rheumatic drugs by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.